Provided by Tiger Trade Technology Pte. Ltd.

Sunshine Biopharma Inc.

0.7730
-0.0144-1.83%
Pre-market: 0.81980.0468+6.05%08:42 EDT
Volume:47.52K
Turnover:38.06K
Market Cap:3.00M
PE:-0.08
High:0.8337
Open:0.8053
Low:0.7730
Close:0.7874
52wk High:24.30
52wk Low:0.7730
Shares:3.88M
Float Shares:3.81M
Volume Ratio:0.48
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.0329
EPS(LYR):-14.3739
ROE:-21.92%
ROA:-9.91%
PB:0.11
PE(LYR):-0.05

Loading ...

Sep 16, 2026

Major Issues Report

Form 8-K - Current report
Sep 11, 2026

Major Issues Report

Form 8-K - Current report
Aug 28, 2026

Major Issues Report

Form 8-K - Current report
Aug 28, 2026

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Aug 14, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Aug 14, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Aug 03, 2026

Major Issues Report

Form 8-K - Current report
Jul 20, 2026

Major Issues Report

Form 8-K - Current report
Jul 10, 2026

Major Issues Report

Form 8-K - Current report
Jul 08, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
May 29, 2026

Major Issues Report

Form 8-K - Current report
May 22, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
May 22, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
May 20, 2026

Major Issues Report

Form 8-K - Current report
May 18, 2026

Correspondence

Form CORRESP - Correspondence
May 18, 2026

Correspondence

Form CORRESP - Correspondence
May 15, 2026

Correspondence

Form CORRESP - Correspondence
May 15, 2026

Correspondence

Form CORRESP - Correspondence
May 13, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]